Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination

Clin Exp Immunol. 2007 May;148(2):199-207. doi: 10.1111/j.1365-2249.2007.03384.x.


Persistent infection with oncogenic human papillomavirus (HPV) is a necessary cause of cervical cancer. Moreover, HPV type 16 (and to a lesser degree HPV type 18) is linked with more rare cancers, namely cancer of the vulva, vagina, penis, anus, oropharynx and larynx. Effective prophylactic vaccines have been developed. In this review, we briefly address immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most (cost-)effective strategies for cancer control.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Female
  • Humans
  • Immunization Programs
  • Immunization Schedule
  • Male
  • Mass Screening
  • Papillomaviridae / classification
  • Papillomavirus Infections / complications
  • Papillomavirus Infections / immunology
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Vaccines*
  • Uterine Cervical Neoplasms / prevention & control*
  • Uterine Cervical Neoplasms / virology


  • Papillomavirus Vaccines